Dámaris Carballeira

🩺🫀

[SportsCardiology @Sports_CardioNL]

Athletes and the coronary calcium paradox
https://t.co/u6UxKbruCI
#Athletes #Atherosclerosis #Sportscardiology

[CardioTeca @cardioteca]

✨ Lo mejor de 2025 en el tratamiento de la insuficiencia cardiaca

👉 Descubre las claves que han marcado 2025 en IC: https://t.co/czXN3qAaS1

🧠📈 La IC sigue creciendo y cambia el perfil del paciente: de riesgo “vascular” a uno claramente cardiometabólico (cardiometabolic shift), con auge de la IC-FEp.
💊🛡️ iSGLT2 se consolidan en más escenarios: prevención primaria, muy ancianos, mujeres con IC-FEp y en la “vida real” de la IC + fibrilación auricular.
⚖️🔥 Nuevas vías en IC-FEp con obesidad: semaglutide y tirzepatide mejoran síntomas y capacidad funcional, complementando la terapia base.
🧪🎯 Medicina de precisión en marcha: vericiguat con inicio acelerado (VELOCITY), aficamten en MCH obstructiva (SEQUOIA-HCM) y acetazolamida IV para optimizar descongestión en IC aguda.

[Julia Seller @JuliaSellerm]

Lo mejor del año 2025 en insuficiencia cardiaca #cardio #heartfailure

[Diego Segura-Rodríguez @SeguraCardio]

📌Implantable Cardioverter-Defibrillator & Sports Participation in Patients With Cardiomyopathy

#Review #ICD #SportsCardiology

[REC Publications @RevEspCardiol]

Impacto pronóstico de los factores psicosociales en la cardiopatía isquémica crónica: aspectos que recordar #reccardioclinics #Aheadofprint @Marisolbravoam2 @dami_carpu https://t.co/0FVLybBKZQ

[CardioTeca @cardioteca]

🫀 Lo mejor del 2025 en imagen cardiovascular

Lee el artículo completo y descubre las claves que marcaron la imagen CV en 2025: https://t.co/Ug6o3HgvKW

🤖 IA en cardiología: del ECG “inteligente” a modelos que afinan el diagnóstico en eco (ojo: 1 de cada 3 informes automáticos de ECG requiere corrección médica).
🫀 Ecocardiografía en IC: enfoque más fenotípico y hemodinámico (IC avanzada), eco de esfuerzo en HFpEF y la grasa epicárdica como marcador con valor pronóstico.
🩺 Intervencionismo estructural: más protagonismo de la eco intracardíaca, actualización de TEE intraoperatorio (AHA 2025) y protocolos post-TAVI más estandarizados.
📈 Imagen avanzada y cardio-oncología: strain como herramienta para detectar disfunción subclínica y guías 2025 que refuerzan la vigilancia en tratamientos cardiotóxicos (antraciclinas/trastuzumab).

[SportsCardiology @Sports_CardioNL]

Clinical Outcome in Athletes With Ventricular Ectopic Beats and Normal Cardiac MRI: Preliminary Results of a Longitudinal Study
https://t.co/RSYVawFERA
#sportscardiology #arrhythmias #CMR

[Elena Plaza Moreno 💓 Urgencias y emergencias @urgenciasemerge]

Ya tenemos las nuevas #guías de #RCP 2025 disponibles. De momento te dejo un resumen de los principales cambios en las guías #ERC y un chatbot para que puedas preguntar lo que quieras.
https://t.co/7sOytgUkDb
#CPRguidelines

[REC Publications @RevEspCardiol]

Impacto pronóstico de los factores psicosociales en cardiopatía isquémica crónica: aspectos que recordar #reccardioclinics #Aheadofprint @Marisolbravoam2 @dami_carpu https://t.co/CUqgcuzymJ

[Alberto Jiménez @jotalbertojota]

🔔¡Hoy han salido las nuevas guías europeas de valvulopatías!

Y vienen cargaditas..

¿Revisamos los principales cambios y novedades? 👇

Abro hilo🧵

[Alberto Jiménez @jotalbertojota]

🚨🫀 #ESC2025 en Madrid está dejando MUCHA tela que cortar.

Aquí va un hilo 🧵 con lo más 🔝 para la práctica clínica

(En cristiano, pero científico..)

Spoiler: algunos estudios cambian lo que hacemos mañana en consulta
👇

(A los opositores MIR: esto NO entra❤️🫶😂)

[Diego Segura-Rodríguez @SeguraCardio]

🚨 Antithrombotic therapy after coronary artery bypass graft surgery🫀

Clinical Consensus 📝 of the @escardio WG on Cardiovascular Surgery & WG on Cardiovascular Pharmacotherapy & @EACTS

#PositionPaper #ESC25 #ESCCongress #DAPT #CardiacSurgery

[European Society of Cardiology @escardio]

NEW Focused update of the 2019 #ESCGuidelines on #dyslipidaemias : https://t.co/YomhOTHtNt

#lipids #riskfactors #cvprev

[Alfonso Valle @ValleAlfonso]

🚨 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
#Cardiology #ESC2025 #LipidUpdate

1️⃣ NEW cardiovascular risk estimation:
Use updated #SCORE2 & #SCORE2OP algorithms for 10-year risk in adults aged 40–89, calibrated to local mortality rates.
Risk categories: Very High, High, Moderate, Low.

2️⃣ LDL-C remains the main target ⚡
Lowering #LDLC reduces #ASCVD risk—start pharmacological therapy at thresholds determined by risk and baseline LDL-C.
Goal: “The lower, the better!”

3️⃣ 👨‍⚕️📉 Innovations in therapy 🧪
•Bempedoic acid now recommended for statin-intolerant/high-risk patients!
•Evinacumab for homozygous familial hypercholesterolemia (FH).
•Inclisiran: ongoing trials, promising ~50% LDL-C reduction.

4️⃣ Acute coronary syndromes (ACS): Early & intensive lipid lowering 🏥
•Initiate high-intensity statin + ezetimibe during ACS hospitalization.
•Combination therapy = Faster & deeper LDL-C reductions, improved outcomes.

5️⃣ Lipoprotein(a): Causal role confirmed
•Measure #Lp(a) at least once in all adults.
•Levels >50 mg/dL (≥105 nmol/L) are risk-enhancing, require aggressive management.

6️⃣ Hypertriglyceridaemia update
•Statins first-line; fibrates not indicated for CV event reduction.
•High-dose icosapent ethyl (4g/day) for high-risk patients with tg 135–499 mg/dL, proven CV event reduction.
•Volanesorsen for familial chylomicronaemia syndrome.

7️⃣ Special populations
•HIV: Statins recommended ≥40 years regardless of LDL-C.
•Oncology: Statins considered in high CV toxicity risk during anthracyclines.

8️⃣ Dietary supplements: 🚫 NOT recommended
•No supplement/vitamin without proven safety & LDL-C efficacy reduces #ASCVD risk.
•Statins and evidence-based therapies continue to lead.

#Guidelines #ESC #Dyslipidaemia #PreventiveMedicine

[Alfonso Valle @ValleAlfonso]

🚨 New study alert for cardiologists & geriatric care!

🚨 Multidomain Rehabilitation for Older
Patients with Myocardial Infarction

#Cardiology #Geriatrics #MyocardialInfarction #Rehabilitation

1/ Older patients (≥65) post-MI with impaired physical function often underrepresented in trials.
👵👴 Older adults post-heart attack are often underrepresented in trials. This changes! #CardioRehab #ElderlyCardiology #HeartHealth

2/ This randomized trial (N=512, median age 80) in Italy compared a multidomain rehab intervention vs usual care.
#CardioRehab #ElderlyCardiology #HeartHealth

3/ Intervention included: cardiovascular risk control, dietary counseling, and structured exercise training over 12 months.
🏥💪 Multidomain approach: risk control + diet + exercise #CardioRehab #ElderlyCardiology #HeartHealth

4/ Primary outcome: CV death or unplanned CV hospitalization within 1 year.
#CardioRehab #ElderlyCardiology #HeartHealth

5/ Result: Intervention group had significantly fewer primary outcome events (12.6% vs 20.6%, HR 0.57, P=0.01).
📉 Significant reduction in heart complications & hospital visits!

6/ Intervention reduced unplanned hospitalizations, especially for heart failure (HR 0.20).

7/ Physical function and quality of life improved with the intervention.
🌟 Better physical function & quality of life

8/ No serious adverse events reported with the intervention.

9/ Tailored, long-term, multidomain rehab could be key in older post-MI care.
💡 Tailored, long-term rehab plans are vital for our aging patients.

10/ Limitations: selected 1-month survivors, patients aware of group allocation, unclear impact of home exercise alone.

📎 https://t.co/kzPLUAAvHh

[Jon Zubiaur Zamacola @JonZubiaur]

Muy interesante la editorial de @Marisolbravoam2 sobre nuestro estudio RECORVAL. Agradecimientos en nombre de todos los autores por tu valiosa perspectiva y destacaría la importancia de una visión global y socioeconómica de los pacientes isquémicos.

https://t.co/Z92ed8jRO8

[REC Publications @RevEspCardiol]

Efficacy and safety of creatine supplementation in patients with heart failure and reduced ejection fraction: a pilot study #reccardioclinics @Josec_lc @LauraFuertesKen @Doctorabellan @fedesoriaarcos @_rMarmol_ @JACastilloMo https://t.co/8f29isMJrM

[REC Publications @RevEspCardiol]

Creatina, el suplemento de moda en deportistas, ¿útil en insuficiencia cardiaca? #reccardioclinics @dami_carpu @DrDavidDobarro @maria_viu https://t.co/KMQHzvUbP8

[Iñigo San Millán @doctorinigo]

As a follow-up to my post yesterday on the somatic mutation theory vs. the mitochondrial (metabolic) theory of cancer, it is important to highlight that mitochondrial dysfunction is not a singular or isolated event—it is a multifactorial process with various possible causes.

As I discuss in this paper, https://t.co/h2uFDBTsIy, mitochondrial dysfunction or decay is well documented to arise from a range of contributors, including genetic mutations, infections, aging, and physical inactivity. Therefore, it is important not to oversimplify the term "mitochondrial dysfunction" when considering it as a root cause of cancer, as this dysfunction is often a downstream consequence of diverse or multifaceted upstream insults.

Furthermore, as discussed in my paper and illustrated in the figure below, mitochondrial dysfunction or decay also plays a central role in the pathogenesis of numerous diseases characterized by profound disruptions in cellular bioenergetics.

[Alfonso Valle @ValleAlfonso]

Finerenone with Empagliflozin in Chronic
Kidney Disease and Type 2 Diabetes

🔗 https://t.co/uJo4HA0OFc

🧵1NEW in @NEJM: Combining #Finerenone + #Empagliflozin significantly reduced albuminuria in patients with #CKD & #T2D.
The CONFIDENCE trial offers a new strategy in tackling cardiorenal risk.
#CardioTwitter #NephTwitter #EndoTwitter

👥 Who were the patients?
•CKD: eGFR 30–90 ml/min/1.73m²
•Albuminuria: UACR 100–5000 mg/g
•All had T2D
•All on RAS inhibitors
✅ Randomized to:

1.Finerenone
2.Empagliflozin
3.Both combined
#Diabetes #Nephrology

🎯 Primary endpoint:
Reduction in urinary albumin-to-creatinine ratio (UACR) at 180 days.
📉 Combo therapy reduced UACR:
•🆚 Finerenone: −29% more
•🆚 Empagliflozin: −32% more
All statistically significant (p<0.001)
#SGLT2i #MRAs #Cardiorenal

🛡️ Safety profile:
•No unexpected adverse events
•Low rates of hypotension, hyperkalemia, AKI
•No excess discontinuation
A reassuring signal for dual initiation 💊💊
#PatientSafety #MedTwitter

🧠 Take-home:
✅ Dual blockade with finerenone + SGLT2i > monotherapy in reducing albuminuria
💡 May suggest additive renal protection
🧪 Awaiting hard outcomes (e.g. eGFR slope, CV events)
#RenalProtection #HeartKidneyAxis